Navigation Links
AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Date:6/1/2009

QUEBEC CITY, June 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it presented results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108 (formerly AN-152), in prostate cancer. The presentation was made during yesterday's poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held through June 2, 2009 at the Orange County Convention Center in Orlando, Florida.

The poster (#5163) entitled, "Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists," S. Liu, A. V. Schally, S. Xiong, R. Cote, D. Hawes, L. Fazli, M. Gleave, J. Cai, F. Brands, J. Engel, J. Pinski, investigates the expression of Luteinizing Hormone Releasing Hormone (LHRH) receptors following prolonged exposure to LHRH agonists.

"Results presented are important for the expansion of potential indications for our anti-cancer compound, AEZS-108", stated Juergen Engel, Ph.D., President and CEO of AEterna Zentaris. "While clinical investigations so far focused on gynaecological indications, the new results show continued expression of LHRH receptors in prostate cancer specimens after prolonged use of LHRH agonists; these data provide further support to the investigation of AEZS-108 in hormone-refractory prostate cancer, a major genitourinary cancer indication in male patients."

Results

LHRH receptor expression was demonstrated in more than 95% of 130 prostate cancer specimens analyzed, irrespective of origin (primary tumor, metastases) or patients' prior hormonal treatment (none, castration, LHRH agonist). In all groups, the majority of specimens showed moderate to strong receptor expression. Statistically, strong receptor expression correlated with higher pathologic tumor stage and shorter overall survival.

    Conclusion

    - In virtually all patients with prostate cancer, tumor cells appear to
      express LHRH receptors;
    - Even tumors persisting or relapsing after castration or prolonged
      hormonal treatment with LHRH agonists retain the expression of LHRH
      receptors;
    - The continued expression of these receptors supports the concept of
      targeting prostatic LHRH receptors to deliver cytotoxic therapy based
      on LHRH analogs, such as AEZS-108.

A copy of the abstract is currently available and can be viewed on-line through the ASCO website: http://www.asco.org/.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements, and we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested to do so by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
2. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
3. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
4. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
5. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
6. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
7. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
8. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
9. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
11. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/16/2017)... PARSIPPANY, N.J. (PRWEB) , ... July 16, 2017 ... ... products, laboratory equipment and analytical instruments announced the launch of its new line ... has introduced five rocking and waving shaker models (both analog and digital) for ...
(Date:7/14/2017)... ... July 13, 2017 , ... Dr. Joshua Mondlick has introduced the LANAP® ... practice, Mondlick Perio, in the Phoenix area. Dr. Mondlick is at the ... FDA cleared laser treatment to re-grow bone and with significantly less pain than traditional ...
(Date:7/13/2017)... , ... July 13, 2017 , ... ... accreditation in Specialty Pharmacy. URAC is the independent leader in promoting healthcare quality ... a comprehensive commitment to quality care, improved processes and better patient outcomes. ...
(Date:7/13/2017)... ... July 13, 2017 , ... After 11 years developing and ... Christopher Laing, MRCVS, Ph.D. has been tapped to lead the effort to establish ... the first Executive Director at the newly formed Capital City Innovation effective September ...
Breaking Biology Technology:
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
Breaking Biology News(10 mins):